TO THE EDITOR
In a recent article in Leukemia, Ohyashiki et al 1 reported the case of a chronic myeloid leukemia (CML) patient with imatinibinduced hepatotoxicity. Histological examination revealed lesions compatible with acute viral hepatitis. In the current report, we describe two other cases of serious imatinib-induced hepatotoxicity. Liver biopsies were performed in both patients and histology was compared with Ohyashiki's case.
Case 1: In October 1997, chronic phase Ph-positive CML was diagnosed in a 58-year-old woman. She underwent leukapheresis and was treated with interferon alpha (IFN) and oral cytarabine (YNK1). Nine months after diagnosis, she underwent autologous stem-cell transplantation (ASCT). IFN was reintroduced 1 month after ASCT. Major cytogenetic response was achieved 16 months after ASCT. However, 4 months later, the patient lost the cytogenetic response and imatinib was initiated at a daily dose of 400 mg (February 2001) . At this time, the patient did not have any biochemical abnormalities. Owing to grade 3 hematologic toxicity, imatinib was lowered to a dose of 250 mg, which permitted a stable platelet count. Complete cytogenetic response (CCR) was obtained 3 months after initiation of imatinib and remained for 12 months follow-up. In January 2002, the patient presented with an upper respiratory infection, which was treated with roxithromycin at a daily oral dose of 300 mg for 5 days. After 1 week, the patient presented with jaundice and asthenia concomitant with major hepatic dysfunction: aspartate aminotransferase (ASAT) (3230 U/l: normal range (N)o40 U/l), alanine aminotransferase (ALAT) (2430 U/l: No40 U/l), gamma glutamyltransferase (g-GT) (408 U/l: No80 U/l), total bilirubin (84 mmol/l); alkaline phosphatase (AP) were normal. Grade 3 hematologic toxicity concomitantly reappearred. In view of the grade 4 nonhematologic toxicity (ASAT and ALAT 420 N) and the grade 3 hematologic toxicity, imatinib was stopped. Serologic studies for hepatitis A, B and C were negative. No acute infection with CMV, EBV and herpesvirus was detected by PCR. Ultrasonography of the abdomen revealed a stony gallbladder without bile duct distension. A percutaneous liver biopsy was performed 13 days after interruption of imatinib and histological examination showed acute severe hepatitis cytolysis with mild cholestasis. After interruption of imatinib and roxithromycin, aminotransferases decreased and returned to normal values 5 weeks later. In contrast, total bilirubin increased to a peak value of 458 mmol/L and returned to normal 3 months after interruption of imatinib. One month after interruption of imatinib, 3% metaphases were Ph-positive. As imatinib was the only effective drug in the treatment of this patient's disease, it was reintroduced at a reduced dose of 100 mg after clinical and biological recovery. Six days after reintroduction, it was interrupted owing to grade 2 nonhematological toxicity (ASAT and ALAT: 2.5-5 N). After biological recovery, i.e. 3 months after rechallenge, treatment with IFN 5 millions IU/m 2 /day s.c. was recommenced. Two months after reintroduction of IFN, no hematological response could be achieved. Transaminases were stable at 1.5 N.
Case 2: A 35-year-old woman was diagnosed with Ph-positive CML in February 2000. She underwent leukapheresis and was treated with IFN + cytarabine. After 1 year of IFN-based therapy, she was considered cytogenetically resistant. Therefore, in March 2001, imatinib was initiated at a dose of 400 mg. After 5 months, it had to be interrupted because of serious hepatic dysfunction considered as grade 3 nonhematological toxicity: ASAT (487 U/l), ALAT (159 U/l). At this time, CCR had been achieved. Despite reintroduction of imatinib at reduced doses (300, 250 mg), the same biochemical abnormalities reoccurred, and imatinib was stopped. After 1 month, transaminases peaked at ASAT (268 U/l) and ALAT (866 U/l). At this time, the patient was not receiving any drug. Ultrasonography of the abdomen was normal. Serologic studies for hepatitis A, B and C were negative. A percutaneous liver biopsy was performed 3 months after interruption of imatinib with transaminases (ASAT (46 U/l), ALAT (137 U/l)): acute hepatitis cytolysis consisting of spotty necrosis and some piecemeal necrosis was the main histological lesion. Concomitantly, the hematological situation had deteriorated: relapse occurred 1 month after interruption of imatinib (33% Ph-positive metaphases). After biological recovery, i.e. 4 months after interruption of imatinib, the patient received conventional doses of hydroxyurea and IFN, 5 millions I U/m 2 / day s.c. was added 2 weeks later. Six months after reintroduction of IFN, hematological response was achieved without any cytogenetic response (100% Ph-positive metaphases).
Imatinib mesylate (Novartis, Basel, Switzerland) is a recently developed tyrosine kinase inhibitor. In a phase I trial, seven of 83 chronic-phase patients (8%) presented grade 2 hepatotoxicity. 2 Eight of the 58 patients (14%) with blast-phase CML and relapsed or refractory Ph-positive acute lymphoblastic leukemia developed a grade 3 or 4 hepatotoxicity. 3 In reports of three multiinstitutional phase II trials including more than 1000 patients with chronic, accelerated or blast-phase CML, 4-6 grade 3/4 elevation of transaminases, bilirubin or AP occurred in fewer than 5% of patients. The median time to onset of elevated transaminases or hyperbilirubinemia was 100 days. In 1% of patients, hepatic biochemical abnormalities developed only after 6 months or more of therapy. The levels generally normalize after interruption of imatinib for 1-4 weeks. One patient treated with imatinib at a daily dose of 600 mg had fatal hepatotoxicity while receiving high doses of acetaminophen (paracetamol). A phase II trial including 147 patients with gastrointestinal stromal tumors (GIST) reported grade 3/4 elevation of transaminases or bilirubin in fewer than 5% of patients. 7 No histological examination was described in these different phase I and II trials.
Here we report two cases of hepatitis occurring during treatment with imatinib (Table 1 ). In the first case, we considered the possibility of hepatotoxicity because of the association of imatinib and roxithromycin. Roxithromycin has been shown to be an inhibitor of cytochrome P450 enzyme CYP3A4, although it is not as potent as erythromycin. 8 As imatinib is a competitive inhibitor of the cytochrome P450 enzymes CYP3A4/5, CYP2C9 and CYP2D6, the administration of roxithromycin is expected to result in increased levels of imatinib, thus increasing its toxicity. Both patients had an imatinib 're-challenge' immediately followed by recurrence of biochemical abnormalities, thereby reinforcing the implication of imatinib in the hepatic dysfunction.
In the two cases we report, histological lesions correlated with the biological perturbations; both patients had a hepatocellular pattern of injury (defined as ASAT and ALAT 4eight-fold increase and AP othree-fold increase) and in both cases, histological examination showed cytolytic hepatitis with mild or no cholestasis. Fatty infiltration was absent and there were no granulomas. However, the intensity of the histological lesions was different: in case 1, the biopsy revealed severe hepatocellular degeneration, correlated with high transaminases. In case 2, histological examination showed less severe cytolytic lesions: cytolysis was prominent around the portal tracts and some fibrosis was apparent. These types of lesion were correlated with moderately elevated transaminases and longer course of the illness. The case described by Ohyashiki et al 1 also revealed cytolysis but the lesions were moderate, an aspect correlating with moderately elevated transaminases. The major histological feature of imatinib-induced hepatitis that differentiates it from other causes of hepatitis and specifically viral acute hepatitis is the diffuse pattern of the inflammation at the site of the injury, without any lymphoid follicles. Eosinophils can be present and are of little help for differential diagnosis. In the two cases reported here, the histological diagnosis could easily be made, as the histological lesions were severe and specific. However, in cases of mild lesions, like the one described by Ohyashiki et al, 1 it seems that the histological alterations are less specific. Therefore, care must be taken not to overdiagnose viral hepatitis when faced with such aspecific lobular lymphoid hepatitis.
Imatinib is a new type of anticancer agent that specifically inhibits neoplastic pathways. It has now been successfully used in the treatment of CML and GIST and trials are ongoing or planned in many different indications. As more extensive clinical applications of this new drug are tested, close monitoring of clinical and biochemical adverse events is recommended, especially in patients with previous liver injury or when imatinib is used in association with other drugs. However, we do not recommend reducing the dose under 300 mg/day except for a short re-challenge test, as it could increase the risk of selecting resistant clones. In addition, caution is mandatory at all times during treatment with imatinib, since hepatotoxicity may occur late, as in one of our cases (1 year after the start of imatinib). Spotlight Correspondence
